Drugs / CNS10-NPC-GDNF
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05306457 | May 2022 → Oct 2026 expected | amyotrophic lateral sclerosis | Cedars-Sinai Medical Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02943850 | Apr 2017 → Oct 2019 | amyotrophic lateral sclerosis | Cedars-Sinai Medical Center | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CNS10-NPC-GDNF | “human neural progenitor cells transduced with GDNF (CNS10-NPC-GDNF) differentiated to astrocytes protected spinal motor neurons and were safe in animal models.” PMID 36064599 ↗ Sep 2022 |
| Modality | Cell therapy | “human neural progenitor cells transduced with GDNF” PMID 36064599 ↗ Sep 2022 |
| Route | Other | “CNS10-NPC-GDNF were transplanted unilaterally into the lumbar spinal cord” PMID 36064599 ↗ Sep 2022 |